I was asked some questions regarding my last post on ihub. here was my response.
All excellent questions! It is hard to gauge wall street since many institutions have strict guidelines on investing criteria. We will see a lot more on how amarantus is viewed on wall street after the uplist and at the start of the ess. Really look at the public institutions that have to release their holdings. Remember we have in the past had two disclosers from major institutions stating they may or may not buy, including Fidelity. I would love to see a good partnership and wonder if they have been approached by offers and the company declined waiting to build more value. I think we are getting close to this point. If we get some good data back from either ess or eltropozine on the phase 2b I think we will get the partnership we have been waiting for.
I think Gerald is very eager which is good but also presents challenges. His eagerness has really done a good job diversifying the company. He is now going to have to be precise and execute. I am not too concerned with the dilution because I feel we have gained a lot of value from the money and shares spent. ESS cost a lot of our cash and shares but in my opinion was a steal. Also to note that the company most likely won't be diluting us to buy anymore products any time soon and further dilution (yes we will be diluted further) will provide necessary capital to uplist and move the products forward.
I also would like to hear more from their solid board but when I see us getting publications and getting orphan status and see data then I know they are working hard. That stuff is not easy and is essential to create value and the eye of both doctors and big pharma.
Gerald's performance has been nothing short of spectacular. He has done more since founding the company then anyone would of ever thought. I personally think that NASDAQ oriented institutions are thinking that they wished he worked for them. Remember that these institutions know how to play the game and are the best in the industry at buying cheap shares.
All excellent questions! It is hard to gauge wall street since many institutions have strict guidelines on investing criteria. We will see a lot more on how amarantus is viewed on wall street after the uplist and at the start of the ess. Really look at the public institutions that have to release their holdings. Remember we have in the past had two disclosers from major institutions stating they may or may not buy, including Fidelity. I would love to see a good partnership and wonder if they have been approached by offers and the company declined waiting to build more value. I think we are getting close to this point. If we get some good data back from either ess or eltropozine on the phase 2b I think we will get the partnership we have been waiting for.
I think Gerald is very eager which is good but also presents challenges. His eagerness has really done a good job diversifying the company. He is now going to have to be precise and execute. I am not too concerned with the dilution because I feel we have gained a lot of value from the money and shares spent. ESS cost a lot of our cash and shares but in my opinion was a steal. Also to note that the company most likely won't be diluting us to buy anymore products any time soon and further dilution (yes we will be diluted further) will provide necessary capital to uplist and move the products forward.
I also would like to hear more from their solid board but when I see us getting publications and getting orphan status and see data then I know they are working hard. That stuff is not easy and is essential to create value and the eye of both doctors and big pharma.
Gerald's performance has been nothing short of spectacular. He has done more since founding the company then anyone would of ever thought. I personally think that NASDAQ oriented institutions are thinking that they wished he worked for them. Remember that these institutions know how to play the game and are the best in the industry at buying cheap shares.
